CCTV's 'Xinwen Lianbo' Highlights InnoCare Pharma, Showcasing Accelerated Breakthroughs in Biopharmaceutical Innovation

Recently, CCTV's 'Xinwen Lianbo' aired a major news segment titled 'China's Pharmaceutical Industry Achieves Accelerated Innovation Breakthroughs in the First Half of the Year,' citing InnoCare Pharma. The report stated that in the first half of this year, China's pharmaceutical industry has seen accelerated innovation breakthroughs, with enterprises continuously enhancing their independent R&D capabilities and strengthening the momentum for pharmaceutical development. This year, China's first broad-spectrum targeted anticancer drug (zolbetuximab) began clinical use in major hospitals nationwide, having received approval just eight months after its marketing application was submitted.

The 'Xinwen Lianbo' cameras focused on the production lines and clinical application scenarios of InnoCare Pharma’s independently developed orelabrutinib (Yinuokai) and zolbetuximab (Yinuoxin).

At InnoCare Pharma's Guangzhou manufacturing facility, orelabrutinib has completed production and quality inspection and is now rolling off the line, delivering high-quality innovative medicines to patients.

Real-world prescription footage of zolbetuximab demonstrates the rapid clinical adoption of domestically developed innovative drugs.

Innovation Driven by Original Research Powers Development

InnoCare Pharma is deeply committed to original innovation, continuously enhancing its independent R&D capabilities and accelerating breakthroughs in innovation outcomes.

Novel BTK inhibitor orelabrutinib (Yinuokai)

China's first and only approved BTK inhibitor for the treatment of marginal zone lymphoma

The world's only BTK inhibitor to demonstrate efficacy in a Phase II clinical trial for systemic lupus erythematosus

Novel TRK inhibitor zorelotinib (Yinuoxin)

China's first domestically developed TRK inhibitor approved for marketing

Novel CD19 monoclonal antibody tafasitamab (Minnuokai)

China's first approved CD19 monoclonal antibody for the treatment of relapsed/refractory diffuse large B-cell lymphoma

Novel TYK2 inhibitor sofitinib (ICP-332)

The world's first TYK2 inhibitor to achieve success in a registrational Phase III clinical trial for atopic dermatitis

Novel BCL2 inhibitor mesutoclax (ICP-248)

China's first BCL2 inhibitor to receive Breakthrough Therapy Designation

Diversified strategic expansion accelerating global footprint

As reported by Xinwen Lianbo, innovative medicines have become a standout calling card for China’s high-end products going global.

In 2025, InnoCare Pharma and Zenas entered into a global collaboration exceeding USD 2 billion for autoimmune disease pipelines including orelabrutinib, setting a record at the time for the highest-value out-licensing deal of a domestically developed small-molecule autoimmune drug from China.

22K Views